| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $14.3M | +9.1% | +13.6% |
| SG&A Expense | $9.9M | +48.1% | +121.7% |
| Operating Income | -$24.2M | -22.2% | -41.8% |
| Net Income | -$22.8M | -25.5% | -44.8% |
| EPS (Basic) | -$0.22 | -22.2% | +0.0% |
| EPS (Diluted) | -$0.22 | -22.2% | +0.0% |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $11.9M | +31.3% | +33.7% |
| Short-term Investments | $121.0M | -15.4% | +38.1% |
| Current Assets | $135.1M | -12.7% | +36.9% |
| Total Assets | $138.6M | -12.6% | +23.8% |
| Current Liabilities | $9.5M | -6.7% | -10.2% |
| Total Liabilities | $10.6M |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$37.8M | -116.6% | — |
| Investing Cash Flow | -$45.7M | +33.3% | — |
| Financing Cash Flow | $1.3M | +39.1% | — |
| -14.4% |
| Stockholders' Equity | $128.0M | -13.0% | +28.5% |